Image-aided suicide gene therapy utilizing multifunctional hTERT-targeting adenovirus for clinical translation in hepatocellular carcinoma

Theranostics

Volumn 6, Issue 3, 2016, Pages 357-368

  Kim, Yun Hee ^a   Kim, Kyung Tae ^a   Lee, Sang Jin ^a   Hong, Seung Hee ^b   Moon, Ju Young ^a   Yoon, Eun Kyung ^a,c   Kim, Sukyoung ^a   Kim, Eun Ok ^a   Kang, Se Hun ^a   Kim, Seok Ki ^a   Choi, Sun Il ^a,c   Goh, Sung Ho ^a   Kim, Daehong ^a   Lee, Seong Wook ^d   Ju, Mi Ha ^e   Jeong, Jin Sook ^e   Kim, In Hoo ^a  

^a National Cancer Center   (South Korea)

^b Shinhan University   (South Korea)

^c Ewha Womans University   (South Korea)

^d Dankook University   (South Korea)

^e Dong A University   (South Korea)

Author keywords

Cancer gene therapy; Hepatocellular carcinoma; In vivo imaging; Trans splicing ribozyme

Indexed keywords

ADENOVIRUS VECTOR; APOLIPOPROTEIN E; FLUORODEOXYGLUCOSE F 18; HERPES SIMPLEX VIRUS THYMIDINE KINASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); RIBOZYME; TELOMERASE REVERSE TRANSCRIPTASE; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOENGINEERING; CANCER GENE THERAPY; CANCER GROWTH; CARCINOMA CELL; CELL DAMAGE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG TARGETING; ENHANCER REGION; GENE EXPRESSION; HSVTK GENE; HUMAN; HUMAN CELL; IMAGING SYSTEM; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROMOTER REGION; SEROTYPE; SIGNAL TRANSDUCTION; SUICIDE GENE THERAPY; ADENOVIRIDAE; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC IMAGING; DISEASE MODEL; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; PROCEDURES; TREATMENT OUTCOME;

ADENOVIRIDAE; ANIMALS; CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC IMAGING; DISEASE MODELS, ANIMAL; GENETIC THERAPY; GENETIC VECTORS; MICE, INBRED BALB C; TRANSDUCTION, GENETIC; TREATMENT OUTCOME;

EID: 84969765338     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.13621     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Faloppi L, Scartozzi M, Maccaroni E, et al. Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. Cancer Treat Rev. 2011;37:169-77.
3. Rahbari NN, Mehrabi A, Mollberg NM, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg. 2011;253:453-69.
4. Lou L, Ye W, Chen Y, et al. Ardipusilloside inhibits survival, invasion and metastasis of human hepatocellular carcinoma cells. Phytomedicine. 2012;19:603-8.
5. Lo HW, Day CP, Hung MC. Cancer-specific gene therapy. Adv Genet. 2005;54:235-55.
6. Nettelbeck DM, Jerome V, Muller R. A strategy for enhancing the transcriptional activity of weak cell type-specific promoters. Gene Ther. 1998;5:1656-64.
7. Wu L, Johnson M, Sato M. Transcriptionally targeted gene therapy to detect and treat cancer. Trends Mol Med. 2003;9:421-9.
8. Sullenger BA, Cech TR. Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing. Nature. 1994;371:619-22.
9. Kwon BS, Jung HS, Song MS, et al. Specific regression of human cancer cells by ribozyme-mediated targeted replacement of tumor-specific transcript. Mol Ther. 2005;12:824-34.
10. Hong SH, Jeong JS, Lee YJ, et al. In vivo reprogramming of hTERT by trans-splicing ribozyme to target tumor cells. Mol Ther. 2008;16:74-80.
11. Nagao K, Tomimatsu M, Endo H, Hisatomi H, Hikiji K. Telomerase reverse transcriptase mRNA expression and telomerase activity in hepatocellular carcinoma. J Gastroenterol. 1999;34:83-7.
12. Kotoula V, Hytiroglou P, Pyrpasopoulou A, Saxena R, Thung SN, Papadimitriou CS. Expression of human telomerase reverse transcriptase in regenerative and precancerous lesions of cirrhotic livers. Liver. 2002;22:57-69.
13. Forsyth NR, Wright WE, Shay JW. Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again. Differentiation. 2002;69:188-97.
14. Song MS, Jeong JS, Ban G, et al. Validation of tissue-specific promoter-driven tumor-targeting trans-splicing ribozyme system as a multifunctional cancer gene therapy device in vivo. Cancer Gene Ther. 2009;16:113-25.
15. Lee SJ, Lee SW, Jeong JS, Kim IH. In vivo reprogramming of human telomerase reverse transcriptase (hTERT) by trans-splicing ribozyme to target tumor cells. Methods Mol Biol. 2010;629:307-21.
16. Giavazzi R, Jessup JM, Campbell DE, Walker SM, Fidler IJ. Experimental nude mouse model of human colorectal cancer liver metastases. J Natl Cancer Inst. 1986;77:1303-8.
17. Kwon BS, Jeong JS, Won YS, et al. Intracellular efficacy of tumor-targeting group I intron-based trans-splicing ribozyme. J Gene Med. 2011;13:89-100.
18. van der Poel HG, McCadden J, Verhaegh GW, et al. A novel method for the determination of basal gene expression of tissue-specific promoters: an analysis of prostate-specific promoters. Cancer Gene Ther. 2001;8:927-35.
19. Ghosh SS, Gopinath P, Ramesh A. Adenoviral vectors: a promising tool for gene therapy. Appl Biochem Biotechnol. 2006;133:9-29.
20. Li D, Duan L, Freimuth P, O'Malley BW, Jr. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res. 1999;5:4175-81.
21. Koski A, Kangasniemi L, Escutenaire S, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther. 2010;18:1874-84.
22. Sova P, Ren XW, Ni S, et al. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther. 2004;9:496-509.
23. Ji L, Bouvet M, Price RE, Roth JA, Fang B. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement. Gene Ther. 1999;6:393-402.
24. Edukulla R, Woller N, Mundt B, et al. Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Res. 2009;69:1448-58.
25. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003;426:194-8.
26. McNees CJ, Tejera AM, Martinez P, et al. ATR suppresses telomere fragility and recombination but is dispensable for elongation of short telomeres by telomerase. J Cell Biol. 2010;188:639-52.
27. George J, Banik NL, Ray SK. Knockdown of hTERT and concurrent treatment with interferon-gamma inhibited proliferation and invasion of human glioblastoma cell lines. Int J Biochem Cell Biol. 2010;42:1164-73.
28. Shen Y, Zhang YW, Zhang ZX, Miao ZH, Ding J. hTERT-targeted RNA interference inhibits tumorigenicity and motility of HCT116 cells. Cancer Biol Ther. 2008;7:228-36.
29. Bagheri S, Nosrati M, Li S, et al. Genes and pathways downstream of telomerase in melanoma metastasis. Proc Natl Acad Sci U S A. 2006;103:11306-11.
30. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 2008;7:11-20.
31. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 2010;29:4989-5005.
32. Semela D, Piguet AC, Kolev M, et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol. 2007;46:840-8.
33. Penuelas I, Mazzolini G, Boan JF, et al. Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology. 2005;128:1787-95.